- Home
- ORMP vs IAF Comparison
ORMP vs IAF Comparison
Compare ORMP & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORMP | IAF |
|---|---|---|
| Founded | 2002 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 123.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ORMP | IAF |
|---|---|---|
| Price | $3.48 | $12.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 182.5K | 90.4K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.44% |
| EPS Growth | ★ 838.25 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $3.60 |
| 52 Week High | $3.30 | $4.59 |
Technical Indicators
Market Signals| Indicator | ORMP | IAF |
|---|---|---|
| Relative Strength Index (RSI) | 73.92 | 60.58 |
| Support Level | $2.75 | $12.72 |
| Resistance Level | $3.24 | $13.15 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 96.80 | 56.97 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.